Yellow Dock Allergy Shots: Urban and Roadside Rumex Explained
Yellow dock and curly dock are two common names for the same plant — Rumex crispus — a robust roadside and disturbed-urban Rumex that dominates highway shoulders, vacant lots, and construction-site margins across all 50 US states.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Yellow Dockis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Yellow Dock Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to yellow dock — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of yellow dock allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of yellow dock immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of yellow dock extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for yellow dock allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing yellow dock extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription yellow dock immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat yellow dock allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Yellow Dock?
The biology, taxonomy, and clinical fingerprint of Yellow Dock — the foundation of how SCIT targets it.
Rumex crispus (curly dock / yellow dock) on a highway roadside margin — its wavy-edged leaves and tall russet seed stalks are familiar in all 50 US states. 'Yellow dock' refers to the yellow taproot; 'curly dock' to the wavy leaf margins — same species.
- Scientific name
- Rumex crispus
- Family
- PolygonaceaeBuckwheat family
- Type
- Perennial weed pollen
- Native to
- Europe; naturalized worldwide as one of the most cosmopolitan weeds
- Allergen proteins
- No formally named WHO/IUIS allergen for Rumex crispus (as of 2025)
- Particle size
- 20–28 μm
- Avoidance difficulty
- Moderate
How Yellow Dock Allergy Presents
Symptoms by body system — useful for distinguishing Yellow Dock sensitivity from overlapping allergies and infections.
Respiratory
- Seasonal rhinitis during May–June roadside-pollen peak
- Sneezing and nasal congestion overlapping almost entirely with grass season
- Symptoms worsened near highway shoulders and vacant lots with dense curly dock stands
- Mild asthma flares possible in sensitized individuals
Ocular
- Mild allergic conjunctivitis concurrent with spring rhinitis
- Eye itching and lacrimation during May–June peak
- Typically mild in severity compared to grass or ragweed ocular disease
Dermal
- Oxalic acid in leaves causes irritant contact dermatitis from handling — NOT IgE-mediated pollen allergy
- Rare urticaria in highly sensitized individuals during peak pollen periods
- Herbalist or forager patients may confuse leaf-handling reactions with pollen allergy
Systemic
- Mild fatigue from spring rhinitis during pollen-season commuting near roadside stands
- Most clinical burden from yellow dock sensitization is mild as a standalone sensitization
- Significant disease usually reflects concurrent grass and other weed co-sensitization
Patients who know herbal medicine often bring up yellow dock as a blood tonic or liver herb — and sometimes they're genuinely wondering whether their spring hay fever comes from the same plant. That's actually a teachable moment: the taproot is what herbal medicine uses, and the pollen is what the allergist worries about. Usually grasses are the real culprit, but sometimes yellow dock deserves its own vial position.
When & Where Yellow Dock Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: May through June across all US states; extends slightly into July in northern states and Canada· ~10–12 weeks of significant pollen release, coinciding almost exactly with the Pooideae grass season
US Exposure Map
10 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- High
- MT:
- Low
- ND:
- Low
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- High
- MA:
- Moderate
- OR:
- High
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Moderate
- IL:
- High
- IN:
- Moderate
- OH:
- High
- PA:
- High
- NJ:
- Moderate
- CT:
- Low
- RI:
- Low
- CA:
- High
- NV:
- Low
- UT:
- Low
- CO:
- Moderate
- NE:
- Low
- MO:
- Moderate
- KY:
- Low
- WV:
- Low
- VA:
- Moderate
- MD:
- Moderate
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Moderate
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Moderate
- TX:
- Moderate
- FL:
- Moderate
- AK:
- Low
- HI:
- Low
What Yellow Dock Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Yellow dock cross-reactivity is mediated by pan-allergens shared across Polygonaceae and other weed families — no R. crispus-specific major allergen has been characterized, limiting component-resolved differentiation from other Rumex species (Halbritter et al. 2018 Illustrated Pollen Terminology).
R. crispus is one of the primary species captured by the genus-level dock-sorrel extract
Same Polygonaceae family; yellow dock and Japanese knotweed often colonize the same roadside and disturbed-site habitats
Is SCIT Right for Your Yellow Dock Allergy?
Answer five questions to see whether yellow dock warrants inclusion in your spring allergy shot regimen.
How severe are your spring pollen symptoms during May–June?
The Yellow Dock SCIT Protocol
Yellow dock SCIT uses a non-standardized Rumex crispus extract (W/V or PNU/mL) as one component in a multi-allergen spring vial alongside grass and other weed extracts. Monotherapy is not clinically justified given the evidence base.
Increasing doses of the combined multi-allergen vial. Yellow dock is a minor component; the build-up schedule is determined by the most potent allergen in the vial (typically a Pooideae grass). Pre-seasonal initiation in October–November allows completing build-up before the April pollen onset. The 30-minute post-injection observation period is mandatory.
Maintenance injections at the target maintenance dose sustain immunological tolerance for the full multi-allergen profile. Yellow dock's incremental contribution to the spring program complements the primary grass desensitization.
Completing the full 3–5 year course provides lasting benefit for the entire sensitization profile, including the Rumex component.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Yellow Dock SCIT
No SCIT RCT exists for yellow dock monotherapy. Clinical inclusion in multi-allergen vials follows the AAAAI Allergen Immunotherapy Practice Parameter framework for non-standardized weed pollen extracts (Cox 2011 JACI) in patients with documented IgE sensitization.
- SPT positivity to Rumex extract in European allergy cohorts9%D'Amato et al. 2007, Allergy 62:976–990 — European weed sensitization survey
- Multi-allergen grass SCIT (primary co-allergen) symptom reduction80%Frew 2008, JACI meta-analysis — Pooideae grass SCIT benchmark
Yellow dock's contribution to multi-allergen SCIT vials is supported by documented sensitization data and the general non-standardized weed extract SCIT framework, not by Rumex crispus-specific RCT evidence. The primary benefit of any multi-allergen vial containing yellow dock will come from the grass and major-weed components.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Yellow Dock SCIT Side Effects
Yellow dock SCIT follows the standard inhalant allergen safety profile as part of a multi-allergen vial. Systemic reactions almost always begin within ~30 minutes of an injection; with Curex's at-home program a prescribed epinephrine auto-injector is confirmed on hand and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, so a brief post-injection self-observation is advised for eligible patients.
Local reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site wheal and flare Expected during build-up phase; resolves within hours | Rate 30–50% | Mild |
Injection-site itching | Rate 20–35% | Mild |
Large local reaction (>5 cm) May prompt vial adjustment | Rate 5–10% | Moderate |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or ocular flare | Rate 1–3% | Mild |
Urticaria | Rate 0.1–0.5% per injection | Moderate |
Bronchospasm | Rate <0.1% per injection | Severe |
Anaphylaxis Onset almost always within ~30 min; Curex confirms a prescribed epinephrine auto-injector on hand and Zoom-supervises the first injection from each new vial or concentration | Rate <0.01% per injection | Severe |
SCIT is one of the safest long-term allergy treatments when properly administered and monitored — no fatalities from properly monitored inhalant SCIT in the US have been reported in the past decade. Curex brings that monitoring home for eligible patients: a board-certified allergist oversees the plan, a prescribed epinephrine auto-injector is confirmed on hand before the first injection, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room.
SCIT vs Alternatives for Yellow Dock
Yellow dock sensitization is always managed as part of a broader spring allergy program — the choice is between multi-allergen SCIT, SLIT drops, or seasonal pharmacotherapy for the overall grass-and-weed spring burden.
| Criterion | At-Home SCIT (Curex, multi-allergen vial)Best | SLIT drops | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate (broader spring regimen) | Moderate (extrapolated) | Very low (all 50 states) | Good seasonal control |
| 5-yr cost | $3,500–$15,000 | $1,500–$4,500 | Minimal | $500–$3,000/5 yrs |
| Duration | 3–5 years | 3–5 years | Lifelong disruption | Lifelong use |
| Convenience | Self-administered at home with Curex — weekly, then monthly | Daily at home | Difficult for commuters | Daily medication burden |
| Safety | Excellent — prescribed epi on hand; first dose Virtual Shot Room–supervised | Very high — no injection risk | Excellent | Generally safe |
| Lasting effect | Yes — 7–12+ yrs | Emerging evidence | No | No |
At-Home SCIT (Curex, multi-allergen vial)Best
SLIT drops
Avoidance
Medications
For urban and suburban patients with yellow dock and grass co-sensitization, a combined multi-allergen SCIT vial addresses the spring roadside-exposure burden more comprehensively than pharmacotherapy. Curex builds that combined vial — yellow dock alongside your spring grasses and any other documented weeds — into one weekly at-home shot, with pricing confirmed in a current program quote: a personalized serum sterile-compounded to USP <797>, a board-certified allergist overseeing the plan, a prescribed epinephrine auto-injector confirmed on hand, and the first injection from each new vial or concentration supervised live in the Virtual Shot Room. It addresses the complete spring sensitization profile without weekly clinic trips for eligible patients.
What Yellow Dock SCIT Actually Costs
Most major US insurers cover allergen immunotherapy for documented weed sensitization. Yellow dock (Rumex crispus) is a standard allergen panel weed — verify your plan covers multi-allergen SCIT vials that include weed extract components. Curex at-home IgE testing identifies specific yellow dock sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your yellow dock allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Yellow Dock SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Yes — yellow dock and curly dock are two common names for the same species, Rumex crispus. 'Yellow dock' refers to the plant's prominent yellow taproot, which has been used in herbal medicine for liver support, anemia, and skin conditions (the active compounds are anthraquinone glycosides including nepodin and chrysophanol). 'Curly dock' describes the wavy, crisped margins of the lance-shaped leaves. Botanists prefer 'curly dock' as the primary common name. When you see either name on an allergy panel, both refer to R. crispus — there is no clinical distinction between them.
Yes — these are different exposures with different allergen profiles. Yellow dock pollen allergy is IgE-mediated sensitization to airborne pollen proteins released during May–June pollination. Herbal yellow dock supplements use the dried taproot, which contains anthraquinone compounds rather than the pollen allergens responsible for respiratory symptoms. Someone who takes yellow dock root supplements without respiratory reactions to the pollen may still develop pollen sensitization from environmental exposure, and conversely, someone with pollen allergy does not necessarily react to root preparations. However, if you develop any symptoms after starting yellow dock herbal supplements, consult your allergist for evaluation.
This is one of the most clinically important distinctions for roadside-habitat patients. Both yellow dock (Rumex crispus) and English plantain (Plantago lanceolata) grow along the same roadsides, share a nearly identical May–July pollen season, and both show up on spring allergy panels. The critical difference: English plantain has a validated WHO/IUIS-listed major allergen (Pla l 1, an Ole e 1-like protein) that can be confirmed by serum-specific IgE component testing. Yellow dock has NO characterized major allergen — component testing cannot distinguish genuine Rumex sensitization from pan-allergen cross-reactivity. For a roadside-symptomatic patient, Pla l 1 component testing should always precede any decision to add yellow dock to an SCIT vial.
No published SCIT RCT has tested yellow dock (Rumex crispus) as a monotherapy allergen. Clinical practice based on the AAAAI Allergen Immunotherapy Practice Parameters (Cox 2011 JACI) supports including it as one component in a multi-allergen vial when a patient has documented IgE positivity and a clinically concordant spring exposure history. As a standalone sensitization without co-occurring grass or other weed sensitizations, yellow dock alone is rarely severe enough to justify a 3–5 year SCIT program. The more common scenario is yellow dock as an add-on within a broader grass-and-weed spring desensitization program.
Rumex sensitization, like most aeroallergen sensitizations, can evolve over years of repeated seasonal exposure. Climate change projections suggest extended pollen seasons for Rumex species in northern latitudes (Anderegg et al. 2021 PNAS), with seasons starting earlier and lasting longer per decade. That said, yellow dock as an isolated minor sensitization rarely escalates to severe asthma or anaphylaxis. The more clinically concerning evolution is expansion of the sensitization profile to include additional spring allergens (grasses, plantain) over multiple seasons — which is why characterizing the full spring sensitization with component-resolved testing is important before the profile expands.
Yes — allergen immunotherapy including non-standardized weed extracts can be used in children with well-documented sensitization and inadequately controlled symptoms. The AAAAI Allergen Immunotherapy Practice Parameters support SCIT as appropriate for pediatric patients when indicated. The safety record supports this: a large safety study of self-administered immunotherapy found that across 23,614 patients giving 2,021,600 injections the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots. For yellow dock specifically, pediatric allergists should confirm that the clinical exposure history supports meaningful Rumex exposure (roadside habitats, garden access) before adding it to a child's multi-allergen vial — given the absence of molecular allergen characterization, the clinical history and skin prick test are the primary evidence for inclusion.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.